Trending...
- Legacy Gospel Series Project - New Previously Unreleased Recordings
- Thirst for Japanese Whisky Strong as New Standards Set
- Optimal Empowers Procurement Teams with Expert Best Practices
MUNICH - DelhiScan -- Garching - OncoBeta® GmbH and their subsidiary OncoBeta Therapeutics Pty Ltd. Australia a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanoma Skin Cancers (NMSCs), announced today that the Rhenium-SCT (Rhenium-188 paste) has been registered on the Australian Register of Therapeutic Goods (ARTG), which is the formal requirement for supply and marketing of the medical device. This advanced radionuclide therapy technology offers a non-invasive, single session, painless treatment with little to no scarring for patients suffering from Basal Cell – and Squamous Cell Carcinomas (BCCs and SCCs).
The global incidence of non-melanoma skin cancers has drastically increased over the past few decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Australia having one of the highest incidence rates in the world. According to the Australian Institute of Health and Welfare (AIHW) Non-melanoma skin cancer (NMSC) is the most common cancer diagnosed in Australia, with over 400,000 new cases per year.
"The approval of the Rhenium-SCT in Australia is a great step forward for patients wanting a new non-invasive and painless treatment option for Non-Melanoma Skin cancer." said Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH, "We are committed to bringing back quality of life to skin cancer sufferers."
More on Delhi Scan
Nicholas H. Vetter, Chief Operating Officer of OncoBeta said: "after receiving the TGA approval we will now set up local production to make the Rhenium-SCT even more accessible to clinics, physicians and their patients throughout Australia."
About the Rhenium-SCT® (Skin Cancer Therapy)
The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
More on Delhi Scan
Find out more about the Rhenium-SCT® at www.oncobeta.com
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
The global incidence of non-melanoma skin cancers has drastically increased over the past few decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Australia having one of the highest incidence rates in the world. According to the Australian Institute of Health and Welfare (AIHW) Non-melanoma skin cancer (NMSC) is the most common cancer diagnosed in Australia, with over 400,000 new cases per year.
"The approval of the Rhenium-SCT in Australia is a great step forward for patients wanting a new non-invasive and painless treatment option for Non-Melanoma Skin cancer." said Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH, "We are committed to bringing back quality of life to skin cancer sufferers."
More on Delhi Scan
- Sandline Global Fortifies World-Class Executive Team: Glenn Hopper Joins as Chief Financial Officer
- Syxsense Announces Integration with Microsoft Office 365
- Launch of Trace One E-Sourcing Will Boost Retailers' Private Label Speed to Market
- New Video Streaming Startup, Relax Scenes, Launches Indiegogo Campaign to Support Their Expansion
- Bronx DWI Lawyer Announces New Website
Nicholas H. Vetter, Chief Operating Officer of OncoBeta said: "after receiving the TGA approval we will now set up local production to make the Rhenium-SCT even more accessible to clinics, physicians and their patients throughout Australia."
About the Rhenium-SCT® (Skin Cancer Therapy)
The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located in Garching near Munich, Germany, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.
More on Delhi Scan
- Recording Artist "Cherne" Crystal Brown auditions for Sony Music, Atlantic Records and Capitol Records and it doesn't stop there
- Honorary Oscar-Winner Charles Burnett brings his award winning film on COVID-19 / Black Hollywood to the Prestigious Pan African 2021 Film Festival
- In a year of recession, Lantek closes 2020 with record sales figures and customer numbers
- The Koedo Kawagoe Spring Festival Celebrates the Arrival of Springtime in Kawagoe, Japan
- Aaron's Energy: An Unexpected Journey Through Grief and the Afterlife With My Brilliant Son
Find out more about the Rhenium-SCT® at www.oncobeta.com
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/oncobeta/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Contact
OncoBeta GmbH - Marketing/Public Relations
Schleißheimer Str. 91
85748 Garching n. Munich GERMANY
info@oncobeta.com
+49 (89) 32667330
OncoBeta GmbH - Marketing/Public Relations
Schleißheimer Str. 91
85748 Garching n. Munich GERMANY
info@oncobeta.com
+49 (89) 32667330
Source: OncoBeta GmbH, 85748 Garching Germany
0 Comments
Latest on Delhi Scan
- NEAT Expands Application to Olfactory and Degustation Sensory Diagnostics
- California Pools Opens Atlanta Location, Expanding Its Industry Leadership
- Avionics Veteran Preston Dane joins L2 Aviation as Senior Account Manager
- Durante Rentals Hires Industry Veteran Steve Durante as Chief Sales Officer
- Sandline Global Names Natalie Franke Solutions Architect and Relationship Director
- A+ Editing Launches New Local Publication
- Joyoshare Newly Introduced VidiKit to Improve Video-processing Efficiency
- Aesthetic Mentor Continues National Expansion with New Medical Training Facility in Hartford, Connecticut
- Nigeria Hosts West Africa's Largest Solar-PV Farm - B&S Power Holding Pte, SunnyFred Global Facilitate 200MW Solar-PV Project In Ashama, Delta State
- MiaSolé, Solliance Break World Record Efficiency Of 26.5% On A Tandem Solar Cell Based On A Flexible CIGS Solar Cell On Feb 10, 2021
- 31-year-old retired Master Barber, spa owner develops entrepreneurial masterclass
- Learn how to Start and Grow a CBD Business With CBD Training Academy's Live Online CBD Business Builder 2021 Certification Course
- Fifth Gen Media And Connected Real Estate Magazine Announce The Connected Real Estate Tech Awards
- Bryce Downey & Lenkov Attorneys Selected to Super Lawyers and Leading Lawyers
- Residence Inn Fort Walton Beach, Florida Opens
- WJ CASTLE Awarded Best Transportation Award by PCI
- Truthset Launches Data Partner Badges Program
- Cynthia Parker Joins DeRonja Real Estate
- Sensory Analytics Partners with The Bronx Group for Russia/CIS Region Sales and Support
- AALF 3-Day Virtual Leadership Conference 2021